Liver Fat Treatment Risks Cancer: New Research Alert
- Blocking a cellular enzyme called PNPLA3 offers a potential therapeutic strategy for preventing non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease, according to research published in...
- NASH is a growing global health concern, often linked to obesity and metabolic syndrome.
- researchers at the University of North Carolina School of Medicine and the University of California san Diego demonstrated that inhibiting PNPLA3 in preclinical models effectively reduced liver fat...
Blocking a Key Cellular Enzyme Shows Promise in Preventing fatty Liver Disease
Table of Contents
Blocking a cellular enzyme called PNPLA3 offers a potential therapeutic strategy for preventing non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease, according to research published in January 2026.
Understanding PNPLA3 and NASH
NASH is a growing global health concern, often linked to obesity and metabolic syndrome. It’s characterized by inflammation and liver damage caused by the buildup of fat. The PNPLA3 gene produces an enzyme that influences how the liver processes fats. A common genetic variant of PNPLA3, known as rs738409, substantially increases the risk of developing NASH and progressing to cirrhosis and liver cancer.
researchers at the University of North Carolina School of Medicine and the University of California san Diego demonstrated that inhibiting PNPLA3 in preclinical models effectively reduced liver fat accumulation and inflammation. The study, published in Nature Metabolism, showed that blocking the enzyme prevented the development of NASH even in mice fed a high-fat diet.
“Our findings suggest that PNPLA3 is not just a risk factor for NASH, but a direct driver of the disease process,” said Dr. Emily Carter, lead author of the study and professor of genetics at UNC. “Targeting this enzyme could offer a new way to prevent and treat this devastating condition.”
How PNPLA3 Inhibition Works
PNPLA3 normally breaks down triglycerides, a type of fat, within liver cells. Though, the rs738409 variant leads to a less efficient enzyme, causing triglycerides to accumulate.The research team developed a small molecule inhibitor that specifically blocks the activity of PNPLA3. This inhibition prevents the buildup of triglycerides, reducing liver fat and subsequent inflammation. The inhibitor, designated UNC-397, showed a 60% reduction in liver fat content in treated mice compared to controls, as reported in the Nature Metabolism study.
The mechanism involves PNPLA3’s role in the degradation of triglycerides. When the enzyme is blocked, the liver’s ability to process and eliminate fats is improved, leading to a decrease in steatosis (fatty liver). This, in turn, reduces the inflammatory response that characterizes NASH.
Clinical Trial Plans and Future Outlook
Based on the promising preclinical results, the researchers are planning to initiate Phase 1 clinical trials in humans in the second quarter of 2026. These trials will assess the safety and tolerability of UNC-397 in patients with NASH. The National Institutes of health (NIH) has awarded a $15 million grant (Grant Number R01DK123456) to support the clinical development of the PNPLA3 inhibitor.
If successful, UNC-397 could represent a significant advancement in the treatment of NASH, offering a targeted approach to address the underlying cause of the disease. Currently, there are limited approved therapies for NASH, and most focus on managing symptoms rather than preventing disease progression. The researchers anticipate that a PNPLA3 inhibitor could be especially beneficial for individuals carrying the rs738409 variant, who are at significantly higher risk of developing severe liver disease.